Ganga Pharmaceuticals
Healthcare
539680 BSE
Price unavailable
Close 8 Sep 2026 ₹12.50 +0.82 +7.02% since 20 Nov 2025
Start ₹11.68
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures · TTM
- ROCE
- 2.90%
- Debt to Equity
- 0.13
- EPS (TTM)
- ₹0.10
- Book Value
- ₹14.06
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- —
- ROE
- 1.30%
- Dividend Yield
- 0.00%
- EBITDA
- ₹30.00 L
- 52W High
- —
- 52W Low
- —
Key Insights
Strengths
2- Company has reduced debt.
- Stock is trading at 0.89 times its book value
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.30% over past five years.
- Company has a low return on equity of 1.09% over last 3 years.
- Promoter holding has decreased over last 3 years: -15.8%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 6 | 5 |
| Oscillators | Bullish | 0 | 6 | 3 |
| Moving Averages | Strong Bearish | 8 | 0 | 2 |
Oscillators
Bullish
Bearish
0
Neutral
6
Bullish
3
Overall
Bearish
Bearish
8
Neutral
6
Bullish
5
Moving Averages
Strong Bearish
Bearish
8
Neutral
0
Bullish
2
Key readings
- RSI (14)
- 44.84
- Neutral
- MACD (12,26,9)
- −1.24
- Bullish
- SMA (50)
- 18.36
- Bearish
- SMA (200)
- 12.22
- Bullish
As of , the latest day with price data, so these readings are not current.
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 10Y | +0.86% |
|---|---|
| 5Y | +3.30% |
| 3Y | +2.63% |
| 1Y | +7.66% |
Net profit
| 10Y | +7.18% |
|---|---|
| 5Y | +37.97% |
| 3Y | +35.72% |
| 1Y | +25.00% |
Operating cash flow
| 10Y | Outflow widened by ₹0.26 Cr |
|---|---|
| 5Y | Outflow widened by ₹1.13 Cr |
| 3Y | Outflow widened by ₹1.27 Cr |
| 1Y | Outflow widened by ₹0.73 Cr |
Operating margin· change in pp
| 10Y | −10.74 pp |
|---|---|
| 5Y | +0.18 pp |
| 3Y | +1.50 pp |
| 1Y | +6.34 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2017 | ₹2.63 Cr |
|---|---|
| Mar 2018 | ₹2.73 Cr |
| Mar 2019 | ₹3.18 Cr |
| Mar 2020 | ₹2.99 Cr |
| Mar 2021 | ₹2.27 Cr |
| Mar 2022 | ₹2.32 Cr |
| Mar 2023 | ₹2.47 Cr |
| Mar 2024 | ₹2.58 Cr |
| Mar 2025 | ₹2.48 Cr |
| Mar 2026 | ₹2.67 Cr |
Net profit by year
| Mar 2017 | ₹0.07 Cr |
|---|---|
| Mar 2018 | ₹0.09 Cr |
| Mar 2019 | ₹0.19 Cr |
| Mar 2020 | ₹0.19 Cr |
| Mar 2021 | ₹0.02 Cr |
| Mar 2022 | ₹0.04 Cr |
| Mar 2023 | ₹0.04 Cr |
| Mar 2024 | ₹0.05 Cr |
| Mar 2025 | ₹0.08 Cr |
| Mar 2026 | ₹0.10 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.7 | 1.14 | 1.23 | 1.25 | 1.24 | 1.35 | 1.23 | 1.32 | 1.42 | 1.31 | 1.33 | 1.37 | 1.46 |
| Expenses | 1.6 | 1.07 | 1.28 | 1.23 | 1.23 | 1.28 | 1.3 | 1.27 | 1.41 | 1.42 | 1.33 | 1.39 | 1.39 |
| Operating Profit | 0.1 | 0.07 | −0.05 | 0.02 | 0.01 | 0.07 | −0.07 | 0.05 | 0.01 | −0.11 | 0 | −0.02 | 0.07 |
| OPM % | 5.88% | 6.14% | −4.07% | 1.6% | 0.81% | 5.19% | −5.69% | 3.79% | 0.7% | −8.4% | 0% | −1.46% | 4.79% |
| Other Income | 0.09 | 0.07 | 0.19 | 0.11 | 0.15 | 0.12 | 0.18 | 0.09 | 0.15 | 0.29 | 0.14 | 0.15 | 0.13 |
| Interest | 0.12 | 0.09 | 0.1 | 0.1 | 0.09 | 0.12 | 0.07 | 0.09 | 0.09 | 0.09 | 0.09 | 0.07 | 0.07 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| PBT | 0.04 | 0.02 | 0.01 | 0 | 0.04 | 0.04 | 0.01 | 0.02 | 0.05 | 0.07 | 0.03 | 0.03 | 0.1 |
| Tax % | 25% | 50% | 100% | — | 25% | 25% | 0% | 50% | 20% | 57.14% | −66.67% | 33.33% | 20% |
| Net Profit | 0.03 | 0.02 | 0 | 0 | 0.03 | 0.03 | 0.01 | 0.02 | 0.03 | 0.02 | 0.06 | 0.02 | 0.08 |
| EPS (₹) | 0.07 | 0.05 | 0 | 0 | 0.07 | 0.07 | 0.02 | 0.05 | 0.06 | 0.04 | 0.12 | 0.03 | 0.14 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.44 | 2.45 | 2.63 | 2.73 | 3.18 | 2.99 | 2.27 | 2.32 | 2.47 | 2.58 | 2.48 | 2.67 |
| Expenses | 2.19 | 2.15 | 2.32 | 2.41 | 2.76 | 2.61 | 2.24 | 2.28 | 2.47 | 2.53 | 2.6 | 2.63 |
| Operating Profit | 0.25 | 0.3 | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | 0 | 0.05 | −0.12 | 0.04 |
| OPM % | 10.25% | 12.24% | 11.79% | 11.72% | 13.21% | 12.71% | 1.32% | 1.72% | 0% | 1.94% | −4.84% | 1.5% |
| Other Income | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.17 | 0.25 | 0.26 | 0.3 | 0.24 | 0.44 | 0.28 |
| Interest | 0.33 | 0.33 | 0.32 | 0.28 | 0.25 | 0.24 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 | 0.13 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.06 |
| PBT | 0.05 | 0.07 | 0.11 | 0.13 | 0.26 | 0.26 | 0.04 | 0.06 | 0.05 | 0.06 | 0.09 | 0.13 |
| Tax % | 40% | 28.57% | 27.27% | 23.08% | 30.77% | 23.08% | 50% | 16.67% | 40% | 33.33% | 11.11% | 23.08% |
| Net Profit | 0.03 | 0.05 | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 | 0.1 |
| EPS (₹) | 0.13 | 0.12 | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.1 | 0.1 | 0.1 | 0.17 | 0.17 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.33 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 | 5.91 |
| Reserves | 0.31 | 0.74 | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 | 2.4 |
| Borrowings | 2.14 | 2.19 | 2.14 | 2.05 | 1.87 | 1.47 | 1.73 | 1.93 | 1.83 | 1.36 | 1.42 | 1.09 |
| Other Liabilities | 0.61 | 0.35 | 0.6 | 1.22 | 0.74 | 0.75 | 0.56 | 0.66 | 0.71 | 0.24 | 0.42 | 0.25 |
| Total Liabilities | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8 | 7.99 | 8.65 | 8.97 | 9.65 |
| Fixed Assets | 0.65 | 0.62 | 0.62 | 0.82 | 0.8 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | 0.65 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.05 | 0.5 | 0 | 0 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0 | 0 |
| Other Assets | 4.69 | 6.22 | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | 9 |
| Total Assets | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8 | 7.99 | 8.65 | 8.97 | 9.65 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.27 | −1.05 | 0.05 | 0.24 | 0.11 | −0.31 | −0.18 | −0.21 | −0.04 | −1.26 | −0.58 | −1.31 |
| Investing | −0.18 | −0.83 | 0.62 | −0.14 | 0.28 | 0.37 | 0.28 | 0.19 | 0.49 | 0.13 | 1.18 | 0.24 |
| Financing | −0.06 | 1.9 | −0.33 | −0.36 | −0.45 | −0.29 | −0.1 | 0.03 | −0.44 | 1.14 | −0.33 | 0.82 |
| Net Cash Flow | 0.03 | 0.02 | 0.33 | −0.26 | −0.05 | −0.22 | 0 | 0.01 | 0.01 | 0 | 0.27 | −0.24 |
| Free Cash Flow | 0.23 | −1.06 | 0.01 | −0.02 | 0.08 | −0.32 | −0.2 | −0.22 | −0.05 | −1.28 | −0.68 | −1.35 |
| CFO/OP | 104 | −347 | 29 | 88 | 40 | −66 | −567 | −500 | — | −2,480 | 467 | −3,200 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 109 | 140 | 173 | 211 | 141 | 131 | 132 | 140 | 132 | 130 | 134 | 129 |
| Inventory Days | 288 | 375 | 386 | 359 | 341 | 297 | 333 | 331 | 347 | 362 | 353 | 329 |
| Days Payable | 118 | 98.65 | 183 | 330 | 163 | 160 | 130 | 152 | 171 | 29.2 | 83.77 | 33.69 |
| Cash Conversion Cycle | 279 | 416 | 377 | 240 | 319 | 267 | 335 | 318 | 308 | 463 | 403 | 423 |
| Working Capital Days | 142 | 468 | 429 | 417 | 388 | 449 | 478 | 503 | 477 | 639 | 731 | 856 |
| ROCE % | 8.03% | 6.8% | 6.14% | 5.84% | 7.26% | 7.23% | 3.3% | 3.46% | 3.28% | 3.06% | 3.18% | 2.9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ganga Pharmaceuticals insights
58 extracted metrics across FY15–FY26.
Documents
Frequently Asked Questions about Ganga Pharmaceuticals
What does Ganga Pharmaceuticals Ltd do?
Incorporated in 1989, Ganga Pharmaceuticals Ltd manufactures & trades in Pharmaceuticals & allied products (Ayurveda)
Where is Ganga Pharmaceuticals Ltd (GANGAPHARM) listed?
Ganga Pharmaceuticals Ltd trades under code 539680 on the BSE.
Which sector does Ganga Pharmaceuticals Ltd belong to?
Ganga Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the Return on Equity (ROE) of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd reported a return on equity of 1.30%. Its debt-to-equity ratio is 0.13.
Company Information
Incorporated in 1989, Ganga Pharmaceuticals Ltd manufactures & trades in Pharmaceuticals & allied products (Ayurveda)
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539680.md for Ganga Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.